
KOD Stock Forecast & Price Target
KOD Analyst Ratings
Bulls say
Kodiak Sciences Inc. demonstrates a positive outlook due to the consistent efficacy of its product candidate KSI-101, which has shown significant vision gains in treatment-naive subjects, with over 90% of patients achieving retinal dryness by Week 8. The company's pipeline also highlights strong results for tarcocimab, achieving all secondary endpoints and showcasing an 89% decreased risk of sight-threatening complications, which bolsters confidence in its therapeutic potential. Additionally, ongoing pivotal progress and positive feedback from retinal key opinion leaders (KOLs) further enhance the sentiment surrounding Kodiak’s ABC platform and overall growth trajectory.
Bears say
Kodiak Sciences Inc. has faced significant setbacks in its developmental pipeline, highlighted by multiple trial failures, including the Phase 3 GLEAM and GLIMMER trials for diabetic macular edema and the Phase 2b/3 DAZZLE trial for wet AMD. The company reported a substantial net loss of $61.5 million, equating to $1.16 per diluted share for the third quarter of 2025, which raises concerns about its financial viability. Additionally, risks associated with the failure of its product candidates to meet revenue expectations, secure necessary funding, and advance commercialization efforts further contribute to a negative outlook for the stock.
This aggregate rating is based on analysts' research of Kodiak Sciences Inc and is not a guaranteed prediction by Public.com or investment advice.
KOD Analyst Forecast & Price Prediction
Start investing in KOD
Order type
Buy in
Order amount
Est. shares
0 shares